FY2024 EPS Estimates for Neuronetics Decreased by Analyst

Neuronetics, Inc. (NASDAQ:STIM) – Stock analysts at William Blair decreased their FY2024 earnings per share (EPS) estimates for shares of Neuronetics in a note issued to investors on Tuesday, November 12th. William Blair analyst M. Andrew now forecasts that the company will post earnings per share of ($1.16) for the year, down from their prior forecast of ($0.83). William Blair has a “Market Perform” rating on the stock. The consensus estimate for Neuronetics’ current full-year earnings is ($0.87) per share. William Blair also issued estimates for Neuronetics’ Q4 2024 earnings at ($0.28) EPS, Q1 2025 earnings at ($0.25) EPS, Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.15) EPS and FY2025 earnings at ($0.84) EPS.

Several other brokerages also recently issued reports on STIM. JMP Securities cut their price target on Neuronetics from $7.00 to $3.00 and set a “market outperform” rating on the stock in a report on Wednesday, August 14th. Canaccord Genuity Group cut their target price on Neuronetics from $6.00 to $3.00 and set a “buy” rating on the stock in a research note on Tuesday, August 13th.

Neuronetics Trading Down 10.1 %

NASDAQ STIM opened at $0.71 on Friday. The firm has a market capitalization of $21.52 million, a PE ratio of -0.58 and a beta of 2.21. Neuronetics has a one year low of $0.52 and a one year high of $5.07. The company has a 50-day simple moving average of $0.90 and a 200-day simple moving average of $1.51. The company has a debt-to-equity ratio of 4.90, a quick ratio of 2.37 and a current ratio of 3.16.

Insider Activity at Neuronetics

In other Neuronetics news, Director Robert Cascella bought 100,000 shares of Neuronetics stock in a transaction that occurred on Thursday, September 12th. The stock was purchased at an average cost of $0.75 per share, for a total transaction of $75,000.00. Following the completion of the acquisition, the director now owns 453,098 shares of the company’s stock, valued at approximately $339,823.50. This represents a 28.32 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have purchased 141,776 shares of company stock worth $110,420 over the last quarter. 9.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Legato Capital Management LLC acquired a new stake in Neuronetics during the second quarter valued at $44,000. Landscape Capital Management L.L.C. bought a new stake in Neuronetics during the 3rd quarter valued at approximately $53,000. GSA Capital Partners LLP grew its stake in shares of Neuronetics by 64.5% in the third quarter. GSA Capital Partners LLP now owns 78,642 shares of the company’s stock worth $60,000 after acquiring an additional 30,837 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Neuronetics during the first quarter worth about $62,000. Finally, Gabelli Funds LLC raised its stake in shares of Neuronetics by 88.2% in the second quarter. Gabelli Funds LLC now owns 48,000 shares of the company’s stock valued at $86,000 after purchasing an additional 22,500 shares in the last quarter. 53.59% of the stock is currently owned by institutional investors and hedge funds.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.